The cellular function of SCAP in metabolic signaling.
Journal
Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
27
12
2019
accepted:
31
03
2020
revised:
26
03
2020
pubmed:
10
5
2020
medline:
31
7
2021
entrez:
10
5
2020
Statut:
ppublish
Résumé
Sterol regulatory element binding protein (SREBP) cleavage activating protein (SCAP) is a key regulator of SREBP maturation. SCAP induces translocation of SREBP from the endoplasmic reticulum to the Golgi apparatus, allowing it to regulate cellular triglyceride and cholesterol levels. Previous studies have shown that suppression of SREBP activation in SCAP conditional knockout mice reduced the accumulation of intracellular triglycerides, which eventually causes the development of metabolic diseases such as atherosclerosis, diabetes, hepatic steatosis, and insulin resistance. However, despite the significance of SCAP as a regulator of SREBP, its function has not been thoroughly discussed. In this review, we have summarized the function of SCAP and its regulatory proteins. Furthermore, we discuss recent studies regarding SCAP as a possible therapeutic target for hypertriglyceridemia and hyperlipidemia.
Identifiants
pubmed: 32385422
doi: 10.1038/s12276-020-0430-0
pii: 10.1038/s12276-020-0430-0
pmc: PMC7272406
doi:
Substances chimiques
Intracellular Signaling Peptides and Proteins
0
Membrane Proteins
0
Multiprotein Complexes
0
SREBP cleavage-activating protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
724-729Références
Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology. Nat. Rev. Endocrinol. 13, 710–730 (2017).
pubmed: 28849786
doi: 10.1038/nrendo.2017.91
Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002).
pubmed: 11994399
pmcid: 150968
doi: 10.1172/JCI0215593
Goldstein, J. L., DeBose-Boyd, R. A. & Brown, M. S. Protein sensors for membrane sterols. Cell 124, 35–46 (2006).
pubmed: 16413480
doi: 10.1016/j.cell.2005.12.022
Goldstein, J. L., Rawson, R. B. & Brown, M. S. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch. Biochem. Biophys. 397, 139–148 (2002).
pubmed: 11795864
doi: 10.1006/abbi.2001.2615
Motamed, M. et al. Identification of luminal Loop 1 of Scap protein as the sterol sensor that maintains cholesterol homeostasis. J. Biol. Chem. 286, 18002–18012 (2011).
pubmed: 21454655
pmcid: 3093874
doi: 10.1074/jbc.M111.238311
Radhakrishnan, A., Sun, L. P., Kwon, H. J., Brown, M. S. & Goldstein, J. L. Direct binding of cholesterol to the purified membrane region of SCAP: mechanism for a sterol-sensing domain. Mol. Cell. 15, 259–268 (2004).
pubmed: 15260976
doi: 10.1016/j.molcel.2004.06.019
Sakai, J., Nohturfft, A., Goldstein, J. L. & Brown, M. S. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J. Biol. Chem. 273, 5785–5793 (1998).
pubmed: 9488713
doi: 10.1074/jbc.273.10.5785
Yang, T. et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 110, 489–500 (2002).
pubmed: 12202038
doi: 10.1016/S0092-8674(02)00872-3
Brown, M. S., Radhakrishnan, A. & Goldstein, J. L. Retrospective on cholesterol homeostasis: the central role of scap. Annu. Rev. Biochem. 87, 783–807 (2018).
pubmed: 28841344
doi: 10.1146/annurev-biochem-062917-011852
Zhang, Y., Motamed, M., Seemann, J., Brown, M. S. & Goldstein, J. L. Point mutation in luminal loop 7 of Scap protein blocks interaction with loop 1 and abolishes movement to Golgi. J. Biol. Chem. 288, 14059–14067 (2013).
pubmed: 23564452
pmcid: 3656263
doi: 10.1074/jbc.M113.469528
Espenshade, P. J. & Hughes, A. L. Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41, 401–427 (2007).
pubmed: 17666007
doi: 10.1146/annurev.genet.41.110306.130315
Sokolov, A. & Radhakrishnan, A. Accessibility of cholesterol in endoplasmic reticulum membranes and activation of SREBP-2 switch abruptly at a common cholesterol threshold. J. Biol. Chem. 285, 29480–29490 (2010).
pubmed: 20573965
pmcid: 2937980
doi: 10.1074/jbc.M110.148254
Afonso, M. S. et al. Molecular pathways underlying cholesterol homeostasis. Nutrients 10, 760 (2018).
pmcid: 6024674
doi: 10.3390/nu10060760
Dong, X. Y., Tang, S. Q. & Chen, J. D. Dual functions of Insig proteins in cholesterol homeostasis. Lipids Health Dis. 11, 173 (2012).
pubmed: 23249523
pmcid: 3564778
doi: 10.1186/1476-511X-11-173
Bi, X., Corpina, R. A. & Goldberg, J. Structure of the Sec23/24-Sar1 pre-budding complex of the COPII vesicle coat. Nature 419, 271–277 (2002).
pubmed: 12239560
doi: 10.1038/nature01040
Sun, L. P., Li, L., Goldstein, J. L. & Brown, M. S. Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J. Biol. Chem. 280, 26483–26490 (2005).
pubmed: 15899885
doi: 10.1074/jbc.M504041200
Radhakrishnan, A., Ikeda, Y., Kwon, H. J., Brown, M. S. & Goldstein, J. L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl Acad. Sci. USA 104, 6511–6518 (2007).
pubmed: 17428920
doi: 10.1073/pnas.0700899104
Nohturfft, A., Yabe, D., Goldstein, J. L., Brown, M. S. & Espenshade, P. J. Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes. Cell 102, 315–323 (2000).
pubmed: 10975522
doi: 10.1016/S0092-8674(00)00037-4
Espenshade, P. J., Li, W. P. & Yabe, D. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. Proc. Natl Acad. Sci. USA 99, 11694–11699 (2002).
pubmed: 12193656
doi: 10.1073/pnas.182412799
Ye, J. & DeBose-Boyd, R. A. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb. Perspect. Biol 3, a004754 (2011).
pubmed: 21504873
pmcid: 3119913
doi: 10.1101/cshperspect.a004754
van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112–124 (2008).
pubmed: 18216768
pmcid: 2642958
doi: 10.1038/nrm2330
Breslow, D. K. & Weissman, J. S. Membranes in balance: mechanisms of sphingolipid homeostasis. Mol. Cell. 40, 267–279 (2010).
pubmed: 20965421
pmcid: 2987644
doi: 10.1016/j.molcel.2010.10.005
Gong, Y. et al. Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell Metab. 3, 15–24 (2006).
pubmed: 16399501
doi: 10.1016/j.cmet.2005.11.014
McFarlane, M. R., Liang, G. & Engelking, L. J. Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine. J. Biol. Chem. 289, 2148–2156 (2014).
pubmed: 24337570
doi: 10.1074/jbc.M113.524041
DeBose-Boyd, R. A. & Ye, J. SREBPs in lipid metabolism, insulin signaling, and beyond. Trends Biochem. Sci. 43, 358–368 (2018).
pubmed: 29500098
pmcid: 5923433
doi: 10.1016/j.tibs.2018.01.005
Moon, Y. A. et al. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15, 240–246 (2012).
pubmed: 22326225
pmcid: 3662050
doi: 10.1016/j.cmet.2011.12.017
Zhang, X., Ji, X., Wang, Q. & Li, J. Z. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell 9, 164–177 (2018).
pubmed: 28643267
doi: 10.1007/s13238-017-0436-0
Mu, W. et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues. Front. Pharm. 9, 1566 (2018).
doi: 10.3389/fphar.2018.01566
Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15, 104–116 (2015).
pubmed: 25614320
pmcid: 4669071
doi: 10.1038/nri3793
Ito, A. et al. Cholesterol accumulation in CD11c(+) Immune cells is a causal and targetable factor in autoimmune disease. Immunity 45, 1311–1326 (2016).
pubmed: 28002731
pmcid: 5181791
doi: 10.1016/j.immuni.2016.11.008
Westerterp, M. et al. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell Metab. 25, 1294–1304 e1296 (2017).
pubmed: 28479366
pmcid: 5514787
doi: 10.1016/j.cmet.2017.04.005
Guo, C. et al. Cholesterol homeostatic regulator SCAP-SREBP2 Integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity 49, 842–856 e847 (2018).
pubmed: 30366764
doi: 10.1016/j.immuni.2018.08.021
Ouyang, N. et al. Dysfunction of cholesterol sensor SCAP promotes inflammation activation in THP-1 macrophages. Exp. Cell Res. 367, 162–169 (2018).
pubmed: 29596892
doi: 10.1016/j.yexcr.2018.03.032
Uttarwar, L., Gao, B., Ingram, A. J. & Krepinsky, J. C. SREBP-1 activation by glucose mediates TGF-beta upregulation in mesangial cells. Am. J. Physiol. Ren. Physiol. 302, F329–F341 (2012).
doi: 10.1152/ajprenal.00136.2011
Rosenfeld, M. E. & Ross, R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 10, 680–687 (1990).
pubmed: 2403295
doi: 10.1161/01.ATV.10.5.680
Yuan, Y. et al. Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro. Am. J. Physiol. Ren. Physiol. 301, F236–F243 (2011).
doi: 10.1152/ajprenal.00646.2010
Zhou, C. et al. Enhanced SCAP glycosylation by inflammation induces macrophage foam cell formation. PLoS ONE 8, e75650 (2013).
pubmed: 24146768
pmcid: 3797718
doi: 10.1371/journal.pone.0075650
York, A. G. et al. Limiting cholesterol biosynthetic flux spontaneously engages Type I IFN signaling. Cell 163, 1716–1729 (2015).
pubmed: 26686653
pmcid: 4783382
doi: 10.1016/j.cell.2015.11.045
Boshuizen, M. C. et al. Interferon-beta promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms. Cytokine 77, 220–226 (2016).
pubmed: 26427927
doi: 10.1016/j.cyto.2015.09.016
Chen, W. et al. ER adaptor SCAP translocates and recruits IRF3 to perinuclear microsome induced by cytosolic microbial DNAs. PLoS Pathog. 12, e1005462 (2016).
pubmed: 26900919
pmcid: 4762662
doi: 10.1371/journal.ppat.1005462
Engelking, L. J., Cantoria, M. J., Xu, Y. & Liang, G. Developmental and extrahepatic physiological functions of SREBP pathway genes in mice. Semin. Cell Dev. Biol. 81, 98–109 (2018).
pubmed: 28736205
doi: 10.1016/j.semcdb.2017.07.011
Kidani, Y. et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 14, 489–499 (2013).
pubmed: 23563690
pmcid: 3652626
doi: 10.1038/ni.2570
McFarlane, M. R. et al. Scap is required for sterol synthesis and crypt growth in intestinal mucosa. J. Lipid Res. 56, 1560–1571 (2015).
pubmed: 25896350
pmcid: 4513997
doi: 10.1194/jlr.M059709
Tang, J. J. et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 13, 44–56 (2011).
pubmed: 21195348
doi: 10.1016/j.cmet.2010.12.004
Casaschi, A. et al. The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. J. Nutr. 134, 1340–1346 (2004).
pubmed: 15173394
doi: 10.1093/jn/134.6.1340
Miyata, S., Inoue, J., Shimizu, M. & Sato, R. Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (SREBP) Activation. J. Biol. Chem. 290, 20565–20579 (2015).
pubmed: 26140926
pmcid: 4536460
doi: 10.1074/jbc.M115.656975
Mustafa, M., Wang, T. N., Chen, X., Gao, B. & Krepinsky, J. C. SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction. Am. J. Physiol. Ren. Physiol. 311, F614–F625 (2016).
doi: 10.1152/ajprenal.00140.2016
Kamisuki, S. et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16, 882–892 (2009).
pubmed: 19716478
doi: 10.1016/j.chembiol.2009.07.007
Cheng, X., Li, J. & Guo, D. SCAP/SREBPs are central players in lipid metabolism and novel metabolic targets in cancer therapy. Curr. Top. Med. Chem. 18, 484–493 (2018).
pubmed: 29788888
pmcid: 6214187
doi: 10.2174/1568026618666180523104541
Pharr, P. N. & Ogawa, M. Enhancement of the proliferation of murine fetal liver erythroid progenitors by infection with Harvey sarcoma virus. Leukemia 4, 210–215 (1990).
pubmed: 2156115
Choi, Y., Kawazoe, Y., Murakami, K., Misawa, H. & Uesugi, M. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J. Biol. Chem. 278, 7320–7324 (2003).
pubmed: 12496288
doi: 10.1074/jbc.M210283200
Liu, M. et al. Xanthohumol, a prenylated chalcone from beer hops, acts as an alpha-glucosidase inhibitor in vitro. J. Agric. Food Chem. 62, 5548–5554 (2014).
pubmed: 24897556
doi: 10.1021/jf500426z
Mahli, A. et al. Therapeutic application of micellar solubilized xanthohumol in a western-type diet-induced mouse model of obesity, diabetes and non-alcoholic Fatty liver disease. Cells 8, 359 (2019).
pmcid: 6523748
doi: 10.3390/cells8040359